don't miss out on the adventure!

Enter your email below to stay up to date on all our latest events, deals and exclusive product launches.

There was an error. Please try again.
Did you mean
This email appears to be undeliverable.
Would you like to continue?
no thank you. i'll continue shopping
by entering your email, you are signing up for future promotional emails.
Thanks for your interest. We'll keep you informed on our latest events, products, and offers!

The New Age Health Sciences Division leverages its extensive IP portfolio & clinical expertise to develop, market, and distribute a portfolio of research-driven products that address relevant health issues for consumers globally.

New Age Beverages is the only Company in the beverage industry with any substantive intellectual property. The portfolio of brands and IP in New Age's Health Sciences Division addresses everyday fundamental human need-states and bridges the divide between pharmaceuticals and nutraceuticals - delivered in a highly efficacious ready-to-drink form.

‘NHANCED Recovery 12 Pack

‘NHANCED™ Recovery is the most comprehensive pre-operative hydration formula available, developed to enhance surgical outcomes & patient satisfaction.

Addresses all clinically relevant areas of concern when included in the ERAS protocol; Safety, Symptomatic Relief, Metabolic/Immune Support, Patient Attitude, and Hospital Cost.

Developed by physicians based on validated micronutrient scientific principles, meeting the guidelines for the American Society of Anesthesiologists.

Comprehensive formula vs. competition, with additional key micronutrients to improve functionality and promote better results in patients.

Patent | Early Recovery After Surgery

U.S. Application No. 62/685,498
"Compositions of Nutrients and Phytochemicals for Preoperative Functional Beverages in Enhanced Recovery After Surgery (ERAS) Protocols"

Nutrition Facts

Serving Size: 12 fl oz (355 mL)
Servings per Container: 1
Amount Per Serving
Calories 160
Cholesterol 0g
Sodium 120mg
Total Carbohydrate 50g
Dietary Fiber 16g
Total Sugar 26g
Includes Added Sugar 16g
Protein 0g

Calcium 4mg, Potassium 750mg, Folate 100mcg DFE, Magnesium 42mg, Selenium 50mcg, Iron 1mg, Vitamin B6 1mg, Vitamin B12 1mcg, Zing 1mg

PROPRIETARY BLEND (6,682mg) : L-Citrulline, Blueberry Fruit Extract, D-Ribose, N-Acetyl-L-Cysteine, L-Carnitine, Monk Fruit Extract

Percent Daily Values (DV) are based on a 2,000 calorie diet.


Coconut Water from Concentrate, Organic Cane Sugar, Filtered Water, L-Citrulline, D-Ribose, Citric Acid, Tripotassium Citrate, Natural Flavor, Sodium Citrate, Blueberry Fruit Extract, Tri Magnesium Citrate, N-Acetyl-L-Cysteine, L-Carnitine, Steviol Glycosides, L-Selenomethionine, Zinc Gluconate, Monk Fruit Extract, Pyridoxine Hydrochloride (Vitamin B-6), Folic Acid, Methylcobalamin (Vitamin B-12)


New Age's Health Sciences intellectual property encompasses 11 major patents, and cooperative research studies and human trials done with some of the most prestigious and respected institutions in the world.

The portfolio and scientific grounding underpinning the portfolio provides the authority to make verifiable claims and provides the catalyst for evolution of the beverage industry with truly functional healthy beverages. The division's flagship product is 'NHANCED Recovery, a preoperative hydration beverage backed by patented micronutrient science, offering the most comprehensive formula on the market.

In addition to the 'NHANCED platform, New Age's IP portfolio features patents & scientific research addressing major consumer opportunities, including: electrolyte replacement, neurological protection and improvement, cardiovascular health, radiation protection, diabetes treatment, hearing health, and digestive health. The Division intends to continue launching new products into market on a yearly basis, satisfying a broad set of consumer need-states with cutting-edge, clinical-grade solutions.

Our Team

Randy L. Looper | President of New Age Health Sciences Divisions

Randy is a Senior Business Executive with an exceptional performance record in sales, marketing and strategic planning. After spending 23 years in the pharmaceutical industry, he decided to take his experience to the small business and entrepreneurial world where he has led commercial expansion in existing companies, and started new companies from concept to execution with innovative, science-based products. His impressive career spans several Fortune 500 companies such as Monsanto/G.D.Searle, Upjohn/Pharmacia and Pfizer Inc. Randy has developed a broad expertise as an Executive Leader in the Healthcare field, and has since moved on to run the Health Sciences Division with a desire to provide healthier & more clinically effective products, without dangerous side effects. His strong science background, combined with his ability to translate patents & research into marketable products forged a successful path in both the pharmaceutical and nutraceutical industries.

In his career, Randy was actively involved in some of the most successful ‘first to market” product launches in pharmaceutical history, such as Ambien and Celebrex, serving in both a marketing & sales capacity for these multibillion-dollar products. At the request of the President of Pharmacia, Randy developed and built the Specialty Sales Divisions in Urology, Neurology, Orthopedics and Rheumatology medical channels. With experience leading divisions with over 300 personnel & delivering over 700 million dollars of annual sales, he’s earned top performance awards at each company throughout his career.

In his last role as President and CEO of Premier Micronutrient Corporation (PMC), the company experienced steady sales growth as he built the framework to launch 4 consumer verticals that included over 18 different nutritional health products. At PMC, he led the transition from a government-based R&D facility to an expansive international commercial footprint. The increase in commercialized growth culminated in the sale of PMC to New Age Beverages Corporation in May of 2017. Randy is currently serving as the President of the Health Sciences Division at New Age, with the goal of leveraging PMC’s proven science portfolio into healthy functional beverages for the consumer market.

In addition to his Board of Directors responsibilities for PMC, Randy has also served on several Boards and committees involving NFL Cardiovascular and Neurologic safety. This has aligned with his personal interest to help find solutions to unmet medical needs involving Military, First Responders and Professional Athletes.

Gerald M. Haase, M.D. | Chief Medical Officer

Gerald M. Haase is Clinical Professor of Surgery at the University of Colorado, School of Medicine and principal of Rocky Mountain Medical Research. He was co-founder of Premier Micronutrient Corporation, a nutritional science research and development entity that was acquired by public company, New Age Beverages, of which he became Chief Medical Officer. He is the co-founder of CURE, a non-profit foundation assisting China in management of cancer in children. Dr. Haase has been actively involved in medical research and clinical trials for 35 years including the design of central venous access devices, applications for intra-operative radiation therapy in pediatric solid tumors, technical surgical innovations in adult and childhood cancer, and development of novel strategies for antioxidant micronutrient therapy for war fighter protection, adverse clinical conditions, against hazardous exposures and for optimal health.

Dr. Haase received his undergraduate degree from the Johns Hopkins University and M.D. degree from Tufts University School of Medicine with graduate honors in research. His surgical training was at the University of Colorado, Health Sciences Center and he specialized in pediatric surgery and oncology at Children’s Hospital Medical Center, Boston, and Nationwide Children’s Hospital, Columbus, Ohio. He received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program and U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA. He has held certification and re-certification from the American Board of Surgery in General Surgery, Pediatric Surgery and Critical Care.

Academically, he was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado and consultant pediatric surgeon to the Department of the Army at Fitzsimmons Medical Center. Dr. Haase was chairman of the Cancer Committee of the American Pediatric Surgical Association, and vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute. He was a member of the National Board of Directors of the American Cancer Society, chairman of its Task Force on Children and Cancer, a member of its Medical Affairs Committee and its representative to the Alliance for Childhood Cancer. He was also a member of the National Wilms Tumor Study Group.

Dr. Haase also served as chairman of the Board of Scientific Counselors of the Cancer Treatment Research Foundation and as a senior member of the Commission on Cancer of the American College of Surgeons. He was appointed to the Board of Trustees of the National Childhood Cancer Foundation and served on its Medical and Scientific Advisory Board. Dr. Haase has published 180 scientific papers, is the inventor or co-inventor of ten issued U.S. patents for micronutrient and phytonutrient therapy with five pending patents and been the recipient of clinical research grants and contracts funded at a several million-dollar cumulative level.

He has been an editorial reviewer for numerous journals including The Journal of Pediatric Surgery, Cancer, and The American Journal of Diseases of Children and was a member of the editorial board of The Annals of Surgical Oncology. Dr. Haase participates with the International Office of the National Cancer Institute and has been an examiner in pediatric surgery for the American Board of Surgery. He is a member of more than 25 professional societies including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences, American College of Physician Executives, and is a charter member of the International Society of Pediatric Surgical Oncology. In addition, he served on the Board of Directors of the Pacific Association of Pediatric Surgeons.

Reginald Kapteyn, D.O. | New Age Board of Directors

Reginald Kapteyn, D.O. is currently Director of Vivitris Life Sciences in Spring Lake, Michigan, and is a practicing private practitioner at Orthopedic Associates Muskegon. He also serves as a medical consultant for Hydrocision Inc., where he has helped to develop a novel, minimally invasive high-pressured microwater jet for surgical debridement of chronic tendon injuries. He currently is principal investigator for a Western IRB approved study utilizing the TenJet hydrotenotomy device for chronic medial and lateral elbow pain. He is board certified in physical medicine and rehabilitation. Kapetyn served as an Interventional Pain Fellow at the University of Wisconsin, in the Department of Orthopedics & Rehabilitation. Dr. Kapteyn was also a clinical instructor for the UW School of Medicine, with focused training for interventional spine management.

After his fellowship at the University of Wisconsin, Kapteyn accepted a faculty position at the University of Cincinnati, serving as Medical Director at Drake Hospital, an affiliate hospital with University of Cincinnati Physicians. This includes serving as the Director of inpatient and outpatient pain management, including surgical implantation of neurostimulators, pain pumps, kyphoplasty, endoscopic lumbar decompression, and percutaneous tenotomies. While there he also served as President of the Medical Executive Committee, also serving as an acting member of the drug planning and development committee at University of Cincinnati Hospital. Dr. Kapteyn has expertise in developing cutting edge efficacious, minimally invasive medical devices with full 510K FDA approval for rapid implementation into standard of care practice with distribution channels. Principle investigator on numerous current IRB peer reviewed studies, so that efficacy is established concurrently with device development.

Dr. Kapteyn completed his residency training at Georgetown University Hospital, and his research fellowship was performed at the National Institutes of Health in Bethesda, Maryland where he was a published author. He completed his surgical fellowship training in sports and spine medicine at the University of Wisconsin. Dr. Kapteyn obtained his Doctorate in Osteopathic Medicine from the West Virginia School of Osteopathic Medicine.